Seed Innovations Ltd has announced that its investee Eurox Group has started sales of dronabinol to corporate customers in Germany.
Dronabinol, the primary psychoactive compound in cannabis also known Delta-9-tetrahydrocannabinol, represents a new revenue stream for Eurox, which follows the distribution agreement of Eurox's full-spectrum extracts to pharmacies during the previous quarter. It’s a new milestone for Eurox.
READ: SEED Innovations ups investment in female-led London-based CBD firm South West Brands
Dronabinol preparations, primarily used in pain therapy, have been available under prescription in Germany since 1998 and currently represents a substantial part of the German medicinal cannabis market.
The dronabinol product category has far fewer suppliers competing for the German market than the case of cannabis flower or full-spectrum extracts.
SEED, an investing company focused on the medical cannabis, health and wellness space, has an 8.85% shareholding in Eurox.